TY  - BOOK
AU  - Greil,Richard
AU  - Pleyer,Lisa
AU  - Faber,Viktoria
AU  - Neureiter,Daniel
ED  - SpringerLink (Online service)
TI  - Chronic Myeloid Neoplasias and Clonal Overlap Syndromes: Epidemiology, Pathophysiology and Treatment Options 
SN  - 9783211798928
AV  - RC254-282 
U1  - 616.994 23
PY  - 2010///
CY  - Vienna
PB  - Springer Vienna
KW  - Medicine
KW  - Internal medicine
KW  - Blood transfusion
KW  - Oncology
KW  - Medicine & Public Health
KW  - Internal Medicine
KW  - Blood Transfusion Medicine
N1  - to “Classic” Chronic Myeloproliferative Disorders (CMPDs) — Molecular and Cellular Biology -- Essential Thrombocythemia (ET) -- Polycythemia Vera (PV) -- Primary Myelofibrosis (PMF) [Previously Chronic Idiopathic Myelofibrosid (CIMF), Myelofibrosis with Myeloid Metaplasia (MMM), Agnogenic Myeloid Metaplasia (AMM)] -- Chronic myelogenous leukemia (CML) -- Myelodysplastic Syndromes (MDS) -- Chronic Myelomonocytic Leukemia (CMML) -- Rare Clonal Myeloid Diseases -- De novo “Classic” Paroxysmal Nocturnal Hemoglobinuria (PNH) (Marchiafava-Micheli Syndrome) -- Clonal Bone Marrow Failure Overlap Syndromes
N2  - Introduction The understanding of the genetic, epigenetic, immuno- well as for practicing hematologists or oncologists. logical and biological causes of myeloproliferative dis- Each chapter follows a similar architecture and leads orders has substantially improved in the last few years. through epidemiology, genetic and molecular causes, Together with refined tools in pathology, the successful hematological and clinical findings, prognostic factors establishment of mouse models mimicking at least some and current treatment approaches of the diseases. of the myeloproliferative disorders, and murine models Effort has been made to point out the evolving field of novel drugs in this arena but simultaneously diff- allowing to carefully dissect the role of mutations and gene dosage effects of, for example JAK2, this has led to entiate between standard and experimental treatment ever increasing numbers of modified classification approaches. schemes. It is therefore important for the heamtologist Together with the co-editors and all the authors of or oncologist to keep up with this rapid change in classi- the various chapters I hope that the readers of the book fication language, the upcoming of new entities or differ- will enjoy reading and benefit from the information entiation between, or subclassification of, rare diseases provided
UR  - http://148.231.10.114:2048/login?url=http://link.springer.com/book/10.1007/978-3-211-79892-8
ER  -